Bioheart Inc., of Sunrise, Fla., released preliminary 12-month data from its phase I ANGEL trial, which is testing the firm's autologous cell therapy Adipocell, in congestive heart failure. At the 12-month time point, patients are demonstrating a statistically significant average improvement in ejection fraction (EF) by echocardiogram.